Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2974293 | 1.00 | SIGMAR1 (0.78) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL20719 | 1.00 | SIGMAR1 (0.78) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL21315849 | 0.98 | SIGMAR1 (0.76) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL21315850 | 0.98 | SIGMAR1 (0.76) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL5639480 | 0.92 | SIGMAR1 (0.67) | SIGMAR1ALDH1A1 | |
| SCHEMBL3494735 | 0.88 | SIGMAR1 (0.80) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL4836976 | 0.88 | SIGMAR1 (0.80) | SIGMAR1LMNAPOLBALDH1A1MEN1 | |
| SCHEMBL2419294 | 0.86 | SIGMAR1 (0.60) | SIGMAR1LMNA | |
| SCHEMBL5710391 | 0.86 | SIGMAR1 (0.60) | SIGMAR1LMNAPOLBGAA | |
| SCHEMBL21315846 | 0.85 | SIGMAR1 (0.59) | SIGMAR1LMNAPOLBALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2196775-A | — | — | None | — | — | JP | disclosed |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B V (US) | 2024-07-04 | — | — | US | disclosed |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2024-06-20 | — | — | US | disclosed |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | ASTEX THERAPEUTICS LIMITED (GB) | 2024-01-09 | — | — | US | disclosed |
| US-20230277527-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2023-09-07 | — | — | US | disclosed |
| CN-110139652-B | ROR-gamma modulators | 爱思凯利尔生物科学私人有限责任公司 | 2022-10-11 | — | — | CN | disclosed |
| EP-3532062-B1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES BV (US) | 2022-07-20 | — | — | EP | disclosed |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2022-06-09 | — | — | US | disclosed |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LIMITED (GB) | 2021-04-29 | — | — | US | disclosed |
| US-20210069182-A1 | ROR-GAMMA MODULATORS | ESCALIER BIOSCIENCES B.V. | 2021-03-11 | — | — | US | disclosed |
| US-4940710-A | 7-(substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1990-07-10 | — | — | US | disclosed |
| US-4927825-A | ANTIISCHEMIC, ANTIINFLAMMATORY AGENTS | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1990-05-22 | — | — | US | disclosed |
| EP-0343900-A2 | Piperazine compounds | GLAXO GROUP LIMITED (GB) | 1989-11-29 | — | — | EP | disclosed |
| US-4806541-A | ANTIBACTERIAL AGENTS | HOFFMANN-LA ROCHE INC. (US) | 1989-02-21 | — | — | US | disclosed |
| EP-0288519-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | Bristol-Myers Squibb Company (US) | 1988-11-02 | — | — | EP | disclosed |
| EP-0266576-A2 | 1-Tert-alkyl-substituted naphthyridine and quinoline carboxylic acids as antibacterial agents | Bristol-Myers Squibb Company (US) | 1988-05-11 | — | — | EP | disclosed |
| WO-1988002627-A1 | 1-TERTIARY-ALKYL-SUBSTITUTED NAPHTHYRIDINE- AND QUINOLINE-CARBOXYLIC ACID ANTIBACTERIAL AGENTS | BRISTOL-MYERS COMPANY (US) | 1988-04-21 | — | — | WO | disclosed |
| EP-0230053-A2 | 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids | AMERICAN CYANAMID COMPANY (US) | 1987-07-29 | — | — | EP | disclosed |
| EP-0216345-A2 | Quinoline derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1987-04-01 | — | — | EP | disclosed |
| CN-86106372-A | Quinoline | — | 1987-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230277527-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20240216361-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20210069182-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
| US-20240199607-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | SIGMAR1 958/4885LMNA 646/4885POLB 237/4885 |
| US-20210122749-A1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | SIGMAR1 958/4885LMNA 646/4885POLB 237/4885 |
| US-11866428-B2 | Bicyclic heterocycle compounds and their uses in therapy | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNB1, CCNE1 | SIGMAR1 958/4885LMNA 646/4885POLB 237/4885 |
| US-20220175765-A1 | ROR-GAMMA MODULATORS | RORB, RORC, RORA | SIGMAR1 1215/4885LMNA 2990/4885POLB 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.